Forbes July 19, 2024
As consumer demand has skyrocketed for GLP-1 medications to reduce weight this has created substantial supply issues. Sometimes type 2 diabetic patients can’t obtain medically necessary GLP-1 drugs. This raises questions about ways to possibly prioritize access to these treatments for diabetics and whether government agencies and payers could do more to address this problem.
Glucagon-like peptide 1 receptor agonists are blockbuster drugs in terms of sales. This owes to their ability to help type 2 diabetes patients manage their disease by inducing the pancreas to make more insulin. And it’s due to GLP-1s’ capacity to reduce patients’ weight by curbing hunger and slowing the movement of food from the stomach into the small intestine.
The popularity of the new...
Today's Sponsors
Today's Sponsor